About Me
Dr. Cairncross discovered a chemosensitive brain cancer and led the international clinical trial that established the role of chemotherapy in the treatment of oligodendrogliomas. He also co-discovered with David Louis (Boston) a molecular marker that is used worldwide to diagnose oligodendrogliomas and guide the treatment of patients with this disease. He is a pioneer and champion of precision medicine in the brain
cancer field, striving to improve patient care through genomic analysis of cancer. He continues to lead a wet lab research program at the Cumming School of Medicine and Directs the Charbonneau Cancer Institute at the University of Calgary.